San Antonio, Texas, resident Dawn Johnson contributes to a number of community efforts and nonprofit organizations. Dawn Johnson also belongs to the board of trustees for the South Texas – San Antonio Chapter of the Leukemia and Lymphoma Society (LLS). Programs administered by the LLS include the Student Series.
The Student Series supports the LLS’s mission of finding a cure for lymphoma and improving the quality of life for individuals diagnosed with blood cancers. It engages children in pre-kindergarten through high school in an assortment of character education and philanthropy programs designed to encourage students to participate in fundraising and giving efforts. To maximize that impact students have on the lives of individuals with blood cancers, the series grows alongside students with programs tailored to each individual school level.
Programs in the Student Series include Pennies for Patients, Collect for Cures, and Students of the Year. Each program engages students in fundraising efforts for the LLS, and the Collect for Cures and Students of the Year initiatives involve a leadership development aspect to help motivate team work and creativity. Since the series’ inception, participating students have raised more than $315 million for breakthrough therapies and patient services. Furthermore, the series raised over $26 million during the 2015-2016 school year.
The founder and chief executive officer of DMJ Consulting, Dawn Johnson of San Antonio has previous experience with USAA Marketing. Previously involved with the San Antonio-based charity Haven for Hope, Dawn Johnson currently serves on the board of the Leukemia & Lymphoma Society (LLS).
The world’s largest nonprofit health organization, the Leukemia & Lymphoma Society has been dedicated to curing leukemia, lymphoma, Hodgkin’s disease, and myeloma since 1949. Committed to educating and helping patients afflicted with blood cancers and their families, the organization divides its efforts into several focus areas: research, public policy, and patient services, among others.
Through therapy acceleration programs and the continued financing of academic research, the Leukemia & Lymphoma Society has expanded the realm of blood cancer research to include venture capitalists and pharmaceutical companies in addition to traditional academic collaborations and biotech partnerships. LLS also works to discover and increase outside funding for blood cancer research. For patients undergoing therapy, LLS strives to ensure they receive high-quality, well-coordinated treatments that are covered by insurance. The organization’s patient services are similarly designed to improve patient access to up-to-date therapies and trials.
LLS serves as a central resource for cancer information and services and is able to address the varied support needs of patients and their families. To date, it has invested over $1 billion in blood cancer research.